Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Phase 1/2 study of PTI-801 drug in healthy adults and then in adults with cystic fibrosis , protocol number Proteostasis PTI-801-01

  This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of the drug PTI-801.

  • Age:

    18 Years and Older

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    8

  • Length of Participation:

    30 days

• Mucociliary ClearanceEnrolling

  SHIP CT: Study of hypertonic saline in preschoolers , protocol number SHIP002

  This study is taking place in Europe, Australia and the U.S. It will look at the safety and effectiveness of hypertonic saline compared to isotonic saline (normal saline) in children with CF.

  • Age:

    3 Years to 5 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    6

  • Length of Participation:

    54 weeks

• Anti-InflammatoryEnrolling

  Phase 2 study of lenabasum in people with CF ages 12 and older , protocol number Corbus JBT101-CF-002

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the potential anti-inflammatory drug lenabasum and will use a placebo control.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    10

  • Length of Participation:

    32 weeks

• Anti-InfectiveEnrolling

  TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF , protocol number TEACH-IP-15

  This phase 2 study is taking place at multiple care centers across the U.S. It will look at the effect of adding oral azithromycin to inhaled tobramycin and will use a placebo control.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 100%

  • Number of Visits:

    5

  • Length of Participation:

    14 weeks

• Nutritional-GIEnrolling

  OPTION: Study of AzurRx MS1819 in people with cystic fibrosis and exocrine pancreatic insufficiency who are 18 years and older , protocol number AzurRX AZ-CF2001

  This study will look at the safety and effectiveness of the drug MS1819 as a pancreatic enzyme replacement therapy.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30% or greater

  • Number of Visits:

    10

  • Length of Participation:

    11 weeks

• ObservationalEnrolling

  GI symptoms observational study (GALAXY) , protocol number GALAXY-OB-18

  This study will collect information on gastrointestinal (GI) symptoms that people with CF experience.

  • Age:

    2 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    1

  • Length of Participation:

    29 days

• OtherEnrolling

  Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2

  This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    6

  • Length of Participation:

    49 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.